• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Annovis Bio, Inc.

    Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
    From Annovis Bio, Inc.
    Via GlobeNewswire
    FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Files Patent for New Composition of Matter for Buntanetap
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
    From Annovis Bio, Inc.
    Via GlobeNewswire
    Annovis Bio Announces Pricing of $7.5 Million Public Offering
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Annovis Bio Announces Launch of Proposed Public Offering
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Annovis Bio Announces the Filing of a Groundbreaking Patent
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
    From Annovis Bio, Inc.
    Via Business Wire
    Tickers ANVS
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.